Recent medicinal chemistry of the histamine H3 receptor.
暂无分享,去创建一个
C. Dvorak | N. Carruthers | Michael A Letavic | M. Letavic | A. Barbier | Ann J Barbier | Curt A Dvorak | Nicholas I Carruthers
[1] M. Tozer,et al. 4-Chlorobenzyl sulfonamide and sulfamide derivatives of histamine homologues: the design of potent histamine H3 receptor antagonists. , 1999, Bioorganic & medicinal chemistry letters.
[2] C. Blandizzi,et al. Histamine H3 receptors mediate inhibition of noradrenaline release from intestinal sympathetic nerves , 2000, British journal of pharmacology.
[3] P. Barnes,et al. Effect of an inhaled histamine H3-receptor agonist on airway responses to sodium metabisulphite in asthma. , 1993, British journal of clinical pharmacology.
[4] A. Hancock,et al. A new class of histamine H(3)-receptor antagonists: synthesis and structure-activity relationships of 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolines. , 2003, Bioorganic & medicinal chemistry letters.
[5] Thomas R. Miller,et al. Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties , 2005, Journal of Pharmacology and Experimental Therapeutics.
[6] E. Mignot,et al. PHARMACOLOGICAL ASPECTS OF HUMAN AND CANINE NARCOLEPSY , 1997, Progress in Neurobiology.
[7] P Hyytiä,et al. Increased brain histamine in an alcohol‐preferring rat line, and modulation of ethanol consumption by H3 receptor mechanisms , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] A. Vasudevan,et al. Synthesis and evaluation of potent pyrrolidine H3 antagonists , 2002 .
[9] Min Zhang,et al. Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist , 2005, Journal of Pharmacology and Experimental Therapeutics.
[10] M. Williams,et al. Two Novel and Selective Nonimidazole H3 Receptor Antagonists A-304121 and A-317920: II. In Vivo Behavioral and Neurophysiological Characterization , 2003, Journal of Pharmacology and Experimental Therapeutics.
[11] Michael Williams,et al. Two Novel and Selective Nonimidazole Histamine H3 Receptor Antagonists A-304121 and A-317920: I. In Vitro Pharmacological Effects , 2003, Journal of Pharmacology and Experimental Therapeutics.
[12] P. Heerdt,et al. Increased severity of reperfusion arrhythmias in mouse hearts lacking histamine H3-receptors. , 2003, Biochemical and biophysical research communications.
[13] A. Gupta,et al. A Facile and Scaleable Synthesis of ABT-239, A Benzofuranoid H3 Antagonist , 2005 .
[14] T. Lovenberg,et al. Behavioral characterization of mice lacking histamine H(3) receptors. , 2002, Molecular pharmacology.
[15] H. Haas,et al. The physiology of brain histamine , 2001, Progress in Neurobiology.
[16] T. Lovenberg,et al. Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. , 2001, The Journal of pharmacology and experimental therapeutics.
[17] J. Schwartz,et al. The histamine H3 receptor and its ligands. , 2001, Progress in medicinal chemistry.
[18] G. Fox,et al. Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists. , 2004, Bioorganic & medicinal chemistry letters.
[19] D. Weiner,et al. Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor , 2002, Neuropharmacology.
[20] R. Henry,et al. An efficient multigram synthesis of the potent histamine H3 antagonist GT-2331 and the reassessment of the absolute configuration. , 2004, The Journal of organic chemistry.
[21] J. Schwartz,et al. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor , 1983, Nature.
[22] A. Poso,et al. A Proton Relay Process as the Mechanism of Activation of the Histamine H3-Receptor Determined by 1H NMR and ab Initio Quantum Mechanical Calculations , 2000 .
[23] A. Hancock,et al. Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. , 2003, Life sciences.
[24] M. Tozer,et al. ω-(Imidazol-4-yl)alkane-1-sulfonamides: a new series of potent histamine H3 receptor antagonists , 2002 .
[25] T. Watanabe,et al. Effect of thioperamide, a histamine H3 receptor antagonist, on electrically induced convulsions in mice. , 1993, European journal of pharmacology.
[26] H. Bönisch,et al. Structure of the human histamine H3 receptor gene (HRH3) and identification of naturally occurring variations , 2002, Journal of Neural Transmission.
[27] M. Williams,et al. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. , 2004, Biochemical pharmacology.
[28] E. Bush,et al. In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists. , 2004, Basic & clinical pharmacology & toxicology.
[29] R. Leurs,et al. The histamine H3 receptor: from gene cloning to H3 receptor drugs , 2005, Nature Reviews Drug Discovery.
[30] R. Stadel,et al. Activation of spinal histamine H3 receptors inhibits mechanical nociception. , 2003, European journal of pharmacology.
[31] Walter A. Korfmacher,et al. Pharmacological Characterization of the Novel Histamine H3-Receptor Antagonist N-(3,5-Dichlorophenyl)-N′-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687) , 2003, Journal of Pharmacology and Experimental Therapeutics.
[32] O. Zuiderveld,et al. Non-imidazole histamine H3 ligands. Part III. New 4-n-propylpiperazines as non-imidazole histamine H3-antagonists. , 2005, European journal of medicinal chemistry.
[33] R. Levi,et al. Unmasking of activated histamine H3-receptors in myocardial ischemia: their role as regulators of exocytotic norepinephrine release. , 1994, The Journal of pharmacology and experimental therapeutics.
[34] A. Hancock,et al. A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans. , 2004, Bioorganic & medicinal chemistry letters.
[35] J. Witkin,et al. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. , 2004, Pharmacology & therapeutics.
[36] R. Millán-Guerrero,et al. Nα‐Methylhistamine Safety and Efficacy in Migraine Prophylaxis: Phase I and Phase II Studies , 2003, Headache.
[37] H. Lander,et al. Activation of histamine H3-receptors inhibits carrier-mediated norepinephrine release during protracted myocardial ischemia. Comparison with adenosine A1-receptors and alpha2-adrenoceptors. , 1996, Circulation research.
[38] Sandy J. Wilson,et al. Acute wake‐promoting actions of JNJ‐5207852, a novel, diamine‐based H3 antagonist , 2004 .
[39] P. Desai,et al. Histamine H4 Receptor Mediates Chemotaxis and Calcium Mobilization of Mast Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.
[40] H. H. Refsgaard,et al. Cinnamic amides of (S)-2-(aminomethyl)pyrrolidines are potent H3 antagonists. , 2004, Bioorganic & medicinal chemistry.
[41] M. Decker,et al. Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup , 2002, Behavioural Brain Research.
[42] E. Bush,et al. Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist. , 2004, European journal of pharmacology.
[43] J. Sullivan,et al. 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention. , 2005, Journal of medicinal chemistry.
[44] C. Kamei,et al. Pruritus‐associated response mediated by cutaneous histamine H3 receptors , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[45] J. Hey,et al. Novel H3 receptor antagonists. Sulfonamide homologs of histamine. , 1998, Bioorganic & Medicinal Chemistry Letters.
[46] J. Schwartz,et al. Influence of imidazole replacement in different structural classes of histamine H(3)-receptor antagonists. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[47] D. Farzin,et al. Rodent antinociception following acute treatment with different histamine receptor agonists and antagonists , 2002, Pharmacology Biochemistry and Behavior.
[48] J. Schwartz,et al. Histamine H3‐receptor‐mediated [35S]GTPγ[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors , 2002, British journal of pharmacology.
[49] N. Shankley,et al. From histamine to imidazolylalkyl-sulfonamides: the design of a novel series of histamine H3-receptor antagonists. , 1999, Bioorganic & medicinal chemistry letters.
[50] G. Fox,et al. Perspectives on cognitive domains, H3 receptor ligands and neurological disease , 2004, Expert opinion on investigational drugs.
[51] C. Kamei,et al. Involvement of histamine H3 receptors in scratching behaviour in mast cell‐deficient mice , 2003, The British journal of dermatology.
[52] D. Monti,et al. Sleep and Waking during Acute Histamine H3 Agonist BP 2.94 or H3 Antagonist Carboperamide (MR 16155) Administration in Rats , 1996, Neuropsychopharmacology.
[53] J. Gómez-Ramírez,et al. Presynaptic H3 autoreceptors modulate histamine synthesis through cAMP pathway. , 2002, Molecular pharmacology.
[54] J. Schwartz,et al. Protean agonism at histamine H3 receptors in vitro and in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[55] J. Schwartz,et al. Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists. , 2004, Bioorganic & medicinal chemistry.
[56] J. Schwartz,et al. Anti-inflammatory and antinociceptive properties of BP 2-94, a histamine H(3)-receptor agonist prodrug. , 2000, The Journal of pharmacology and experimental therapeutics.
[57] Craig W Berridge,et al. 4-phenoxypiperidines: potent, conformationally restricted, non-imidazole histamine H3 antagonists. , 2005, Journal of medicinal chemistry.
[58] Youssef L Bennani,et al. Synthesis and SAR of aminoalkoxy-biaryl-4-carboxamides: novel and selective histamine H3 receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.
[59] Nicholas J. Carruthers,et al. Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. , 2001, Molecular pharmacology.
[60] Xiaohong Zhu,et al. Identification of a novel, orally bioavailable histamine H(3) receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template. , 2002, Bioorganic & medicinal chemistry letters.
[61] K. Fink,et al. Involvement of presynaptic H3 receptors in the inhibitory effect of histamine on serotonin release in the rat brain cortex , 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.
[62] R. Leurs,et al. Identification of rat H3 receptor isoforms with different brain expression and signaling properties. , 2001, Molecular pharmacology.
[63] J. Schwartz,et al. Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat , 1990, Brain Research.
[64] J. Sierra,et al. Histamine H3 receptor activation inhibits glutamate release from rat striatal synaptosomes , 2001, Neuropharmacology.
[65] J. A. Jablonowski,et al. A scalable synthesis of a histamine H3 receptor antagonist. , 2004, The Journal of organic chemistry.
[66] T. Lovenberg,et al. Molecular and pharmacological characterization of the mouse histamine H3 receptor. , 2003, European journal of pharmacology.
[67] A. Spek,et al. Synthesis and Structure-Activity Relationships of Conformationally Constrained Histamine H3 Receptor Agonists. , 2003 .
[68] Sandy J. Wilson,et al. Novel human histamine H(3) receptor antagonists. , 2002, Bioorganic & medicinal chemistry letters.
[69] S. Shuto,et al. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure. , 2003, Journal of medicinal chemistry.
[70] J. Rees,et al. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in BalbC mice , 2004, British journal of pharmacology.
[71] A. Vasudevan,et al. Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands. , 2002, Bioorganic & medicinal chemistry letters.
[72] Sylvain Crochet,et al. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. , 2004, Trends in pharmacological sciences.
[73] I. Sobhani,et al. The H3 receptor is involved in cholecystokinin inhibition of food intake in rats. , 2001, Life sciences.
[74] H. Stark,et al. Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats , 1998, Brain Research.
[75] I. D. de Esch,et al. N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist. , 2005, Journal of medicinal chemistry.
[76] R. Bakker. Histamine H3-receptor isoforms , 2004, Inflammation Research.
[77] R. Levi,et al. Activation of histamine H3 receptors inhibits carrier-mediated norepinephrine release in a human model of protracted myocardial ischemia. , 1997, The Journal of pharmacology and experimental therapeutics.
[78] R. Egan,et al. Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig. , 1998, The Journal of pharmacology and experimental therapeutics.
[79] G. Fox,et al. Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs. , 2002, Bioorganic & medicinal chemistry letters.
[80] Holger Stark,et al. Development of a new class of nonimidazole histamine H(3) receptor ligands with combined inhibitory histamine N-methyltransferase activity. , 2002, Journal of medicinal chemistry.
[81] G. Fox,et al. Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1. , 2002, Bioorganic & medicinal chemistry letters.
[82] T. Kenakin,et al. Inverse, protean, and ligand‐selective agonism: matters of receptor conformation , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[83] J. Brioni,et al. Histaminergic ligands attenuate barrel rotation in rats following unilateral labyrinthectomy. , 1998, Methods and findings in experimental and clinical pharmacology.
[84] N. Shankley,et al. Design, Synthesis, and Structure−Activity Relationships of Novel Non-Imidazole Histamine H3 Receptor Antagonists , 2000 .
[85] M. Ichinose,et al. Histamine H3‐receptors inhibit cholinergic neurotransmission in guinea‐pig airways , 1989, British journal of pharmacology.
[86] K. Browman,et al. Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan , 2004, Behavioural Brain Research.
[87] J. Schwartz,et al. Piperidino-hydrocarbon compounds as novel non-imidazole histamine H(3)-receptor antagonists. , 2002, Bioorganic & medicinal chemistry.
[88] H. Kotani,et al. Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. , 2002, The Journal of clinical investigation.
[89] C Liu,et al. Alternative splicing of the histamine H(3) receptor mRNA at the third cytoplasmic loop is not detectable in humans. , 2000, Brain research. Molecular brain research.
[90] W. Chai,et al. Non-imidazole heterocyclic histamine H3 receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.
[91] Y. Yamamoto,et al. Thioperamide, a histamine H3 receptor antagonist, increases GABA release from the rat hypothalamus. , 1997, Methods and findings in experimental and clinical pharmacology.
[92] T D Perkins,et al. Development of a pharmacophore model for histamine H3 receptor antagonists, using the newly developed molecular modeling program SLATE. , 2001, Journal of medicinal chemistry.
[93] J. Brioni,et al. Pharmacological evaluation of an in vivo model of vestibular dysfunction in the rat. , 1998, Methods and findings in experimental and clinical pharmacology.
[94] K. Fink,et al. Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors , 2005, Journal of Neural Transmission / General Section JNT.
[95] J. Schwartz,et al. Search for Histamine H3 Receptor Ligands with Combined Inhibitory Potency at Histamine N‐Methyltransferase: ω‐Piperidinoalkanamine Derivatives , 2004, Archiv der Pharmazie.
[96] K. Rimvall,et al. 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. , 2005, Journal of medicinal chemistry.
[97] J. Schwartz,et al. Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine hH3 receptor affinities. , 2003, Bioorganic & medicinal chemistry.
[98] S. Schulz,et al. Homo- and Heterodimerization of Somatostatin Receptor Subtypes , 2001, The Journal of Biological Chemistry.
[99] R. Egan,et al. Histamine H3 Antagonists , 2001 .
[100] O. Zuiderveld,et al. Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H(3) receptor agonist. , 2004, Journal of medicinal chemistry.
[101] A. Hancock,et al. Species-related pharmacological heterogeneity of histamine H(3) receptors. , 2001, European journal of pharmacology.
[102] H. Lander,et al. Functional identification of histamine H3-receptors in the human heart. , 1995, Circulation research.
[103] C. Dvorak,et al. A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines. , 2003, Journal of medicinal chemistry.
[104] S. M. Knudsen,et al. 1-alkyl-4-acylpiperazines as a new class of imidazole-free histamine H(3) receptor antagonists. , 2004, Journal of medicinal chemistry.
[105] Holger Stark,et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain , 2000, Nature.
[106] J. Hey,et al. Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine. , 2003, Bioorganic & medicinal chemistry letters.